Garland Jonathan Todd 4
4 · Cytek Biosciences, Inc. · Filed Aug 21, 2023
Insider Transaction Report
Form 4
Garland Jonathan Todd
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2023-08-18$8.46/sh−760$6,430→ 7,078 total - Tax Payment
Common Stock
2023-08-18$8.46/sh−1,076$9,103→ 8,763 total - Exercise/Conversion
Restricted Stock Units
2023-08-18−1,951→ 21,462 total→ Common Stock (1,951 underlying) - Exercise/Conversion
Restricted Stock Units
2023-08-18−2,761→ 39,579 total→ Common Stock (2,761 underlying) - Exercise/Conversion
Common Stock
2023-08-18+1,951→ 7,838 total - Exercise/Conversion
Common Stock
2023-08-18+2,761→ 9,839 total
Footnotes (4)
- [F1]Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
- [F3]The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
- [F4]The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.